SCHEMBL5434840

SCHEMBL5434840

N#CC(CC(=O)O)(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.41
MIF P14174 1/20 0.39
CCR1 P32246 1/20 0.39
FFAR1 O14842 1/20 0.38
CTSL P07711 3/20 0.37
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
ATM Q13315 1/20 0.36
KIF11 P52732 1/20 0.36
EPHX2 P34913 1/20 0.35
CYP2D6 P10635 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
OPRM1 P35372 1/20 0.35
DRD3 P35462 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
ALPG P10696 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5441357 0.79 CCR1 (0.38) KCNN4CCR1CYP2C19ATMCYP2D6
SCHEMBL1508237 0.77 MAPT (0.45) CYP2C19OPRM1ALDH1A1LMNA
SCHEMBL4579908 0.76 MIF (0.64) KCNN4MIFFFAR1CYP2C19HIF1A
SCHEMBL7738262 0.76 CTSL (0.37) KCNN4MIFFFAR1CTSLCYP2C19
SCHEMBL1508086 0.76 CCR1 (0.42) KCNN4CCR1CYP2C19ATMCYP2D6
SCHEMBL1508075 0.75 L3MBTL1 (0.35) KCNN4CCR1CTSLCYP2C19ATM
SCHEMBL3160396 0.75 MIF (0.47) KCNN4MIFCYP2C19HIF1AKIF11
SCHEMBL11097461 0.74 FFAR1 (0.41) KCNN4FFAR1CTSLALDH1A1LMNA
SCHEMBL7566897 0.73 CYP2C19 (0.47) KCNN4MIFCYP2C19HIF1ASMN1; SMN2
SCHEMBL29154383 0.73 KCNN4 (0.44) KCNN4MIFFFAR1CYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070027205-A1 Diarylmethyl derivatives as potassium channel modulators NEUROSEARCH A/S (DK) 2007-02-01 US claimed
EP-1644332-A1 DIARYLMETHYL DERIVATIVES AS POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2006-04-12 EP claimed
WO-2005003094-A1 DIARYLMETHYL DERIVATIVES AS POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2005-01-13 WO claimed
US-20070027205-A1 Diarylmethyl derivatives as potassium channel modulators NEUROSEARCH A/S (DK) 2007-02-01 US disclosed
EP-1644332-A1 DIARYLMETHYL DERIVATIVES AS POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2006-04-12 EP disclosed
WO-2005003094-A1 DIARYLMETHYL DERIVATIVES AS POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027205-A1 Diarylmethyl derivatives as potassium channel modulators KCNC1, KCNN3, KCNA1 KCNN4 44/4885MIF 4597/4885CCR1 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.